Safety and optimal dose of intracoronary adenosine 5'-triphosphate for the measurement of coronary flow reserve.
BACKGROUND
Adenosine 5'-triphosphate (ATP) has been demonstrated to have similar vasodilator potency and fewer hemodynamic or electrocardiographic derangements compared with papaverine in the measurement of coronary flow reserve. However, there is little data about its optimal dose and the effect on myocardial lactate metabolism.


METHODS
Under continuous monitoring of the left anterior descending coronary flow velocity with a Doppler guide wire, we investigated the changes of hemodynamics, electrocardiogram, and myocardial lactate metabolism before and after the administration of 50 microg ATP and 10 mg papaverine into the left coronary artery in 18 patients with normal coronary arteries. To determine the optimal dose of ATP for the coronary flow reserve in the left coronary artery, we measured coronary flow velocity with five incremental doses of intracoronary ATP (0.5, 5, 15, 30, and 50 microg) and 10 mg of papaverine in another seven patients.


RESULTS
In contrast to papaverine, ATP did not produce any significant changes in hemodynamics or the electrocardiogram. The increase in the coronary flow velocity of the two agents was similar. Although all patients showed lactate production after the administration of papaverine, only three patients showed lactate production after ATP (p < 0.001). The coronary flow reserve derived from > or = 215 microg of ATP was similar to that derived from papaverine. There was a significant correlation between the coronary flow reserve obtained with > or = 5 microg of ATP and that obtained with papaverine.


CONCLUSIONS
These results suggest that maximal coronary vasodilation in the left coronary artery can be safely obtained with doses > or = 15 microg of intracoronary ATP in patients with normal coronary arteries.
Sonoda
S
S
Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Takeuchi
M
M
Nakashima
Y
Y
Kuroiwa
A
A
D000255:Adenosine Triphosphate / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D006328:Cardiac Catheterization; D002637:Chest Pain / Q000175:diagnosis; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000502:physiology*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D019344:Lactic Acid / Q000096:biosynthesis / Q000097:blood; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D010208:Papaverine / Q000008:administration & dosage; D012449:Safety; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage
D014665:Vasodilator Agents; D019344:Lactic Acid; D000255:Adenosine Triphosphate; D010208:Papaverine